Want to see AU:AGN full AI Analyst Report?
AGN Stock Chart & Stats
AU$0.16
<AU$0.01(3.23%)
At close: 4:00 PM EDT
AU$0.16
<AU$0.01(3.23%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.77
Previous CloseN/A
Volume188.94K
Average Volume (3M)511.75K
Market Cap
AU$19.91M
Enterprise ValueAU$9.09M
Total Cash (Recent Filing)AU$5.04M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding128,456,710
10 Day Avg. Volume288,263
30 Day Avg. Volume511,745
Financial Highlights & Ratios
PEG Ratio-2.24
Price to Book (P/B)13.39
Price to Sales (P/S)30.16
P/FCF Ratio-16.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$4.40M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially lowers solvency risk and removes interest expense pressure, giving management flexibility to allocate scarce cash to R&D, trials, or strategic partnerships. For an early-stage biotech, this preserves optionality during extended development cycles.
Consistent Revenue GrowthYear-over-year revenue expansion demonstrates commercial or program progress and growing underlying demand for the company's offerings. Sustained top-line growth supports gross profit expansion and credibility with partners and investors as the company advances clinical programs.
Focused R&D PipelineA clear, specialized focus on neuroprotective therapeutics creates deep domain expertise, concentrated resource allocation, and clearer go-to-market and partnership pathways. This strategic clarity can strengthen clinical execution and attract collaborators in a high-barrier therapeutic niche.
Bears Say
Large Operating LossesVery large and widening losses erode earned capital and require either sustained external funding or rapid margin improvement to reach breakeven. Persistent negative profitability undermines long-term financial sustainability and increases strategic pressure on management to raise capital or cut programs.
Persistent Cash BurnOngoing negative operating and free cash flow means the business cannot self-fund development activities. This structural cash burn raises the likelihood of periodic equity raises, which dilute shareholders and can disrupt long-term R&D timelines if capital access tightens.
Eroding Equity & Weak ROEA sharp decline in equity and persistently negative ROE signal that prior losses have materially eroded the capital base. Lower equity reduces financial buffer against shocks, increases reliance on external financing, and reflects low capital efficiency in converting investment into returns.
Argenica Therapeutics Ltd News
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.09 and its highest was AU$0.77 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Argenica Therapeutics Ltd’s market cap is AU$19.91M.
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 206 days.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Argenica Therapeutics Ltd released its earnings results on Feb 10, 2026. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.03.
Is Argenica Therapeutics Ltd overvalued?
According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Overvalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 128,456,710 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Argenica Therapeutics Ltd reported an EPS of -AU$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenica Therapeutics Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AGN Sentiment 92%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-66.25%
Trailing 12-Months
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―